All news - Pipelinereview
6 days ago · BERLIN, Germany I December 4, 2024 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today presented the complete data set from its first-in-human proof-of-concept (POC) trial with EVO756 at the 7th GA²LEN Global Urticaria Forum in Berlin, Germany. The podium clinical presentation entitled “EVO756, an
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine …
Oct 10, 2024 · GAITHERSBURG, MD, USA I October 9, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax’s updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and ...
Septerna Announces Initiation of Phase 1 Clinical Trial with SEP …
Sep 27, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Radella Pharmaceuticals Announces Topline Data from the Phase …
Nov 9, 2024 · First-in-human randomized clinical trial demonstrates safety and tolerability of MD-18, Radella’s novel lead asset from its platform targeting cardiometabolic disease and its adjacencies NEW YORK, NY, USA I November 07, 2024 I Radella Pharmaceuticals, LLC., a clinical-stage biopharmaceutical ...
Harbour BioMed Announces Submission of IND Application for …
Nov 9, 2024 · CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SUZHOU, China I November 8, 2024 I Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the submission of an Investigational New Drug (IND) application to the Centre ...
Aurigene Oncology Limited Announces Promising Results of Phase …
Oct 9, 2024 · BENGALURU, India & HYDERABAD, India I October 08, 2024 I Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India’s first trial for a ...
Trueline Therapeutics Announces Completion of IND
May 17, 2023 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for …
SAN DIEGO, CA, USA I July 15, 2014 I La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, …
Lilly's tirzepatide reduced the risk of worsening heart failure events ...
Nov 18, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Skip to content